World Pharmaceutical Frontiers

WPF

Why is World Pharmaceutical Frontiers essential reading?

The pharmaceutical industry is changing faster than ever before. Regulations are becoming more demanding, and there are more technologies, faster product launches and shorter product life cycles. At the same time the cost of R&D is continuously increasing. This is putting heavier financial pressure on pharma to reduce costs and shorten lead times without compromising quality or patient safety, and choosing the right investment has never been more essential.

World Pharmaceutical Frontiers is the premier information source for the world’s leading pharmaceutical companies, with reliable and accurate intelligence on emerging trends and breakthrough technologies to help them make critical business decisions.

Focusing on all areas of the pharmaceutical industry and aimed at senior executives in charge of purchasing, R&D and manufacturing, World Pharmaceutical Frontiers provides a clear overview of the latest industry thinking regarding pharma and is essential reading for those who want to stay ahead of the competition.

Vol. 1 2025

Sterile manufacturing in pharmaceuticals ensures products such as injectables and implants are produced in microorganism-free environments using stringent controls and sterilisation. In contrast, non-sterile manufacturing applies to products like tablets and syrups, focusing on meeting strict microbial limits without requiring sterility. Both processes are essential for ensuring product safety and regulatory compliance. Lorraine Mullaney explores the difference between sterile and non-sterile manufacturing according to the MHRA, speaking to experts along the way. AI-driven delivery Artificial intelligence (AI) has emerged as a transformative force in healthcare, with applications spanning diagnostics to drug development. Now, AI/ML models are revolutionising the design of delivery systems, from improving permeability to creating more effective drug carriers. Monica Karpinski delves into the rapidly evolving field of AI-driven drug delivery systems to explore the implications of these advances.

Vol. 2 2024

AI holds huge promise for enhancing and streamlining quality control processes to get high-quality drugs to patients faster. Elly Earls sat down with Dave Latshaw, chief executive and scientific officer at BioPhy, and Niranjan Kulkarni and Ryan Thompson of CRB Group, to find out about the technology’s most exciting applications and the barriers that still remain before it can be widely implemented. Automatic for the people The promise of smart devices for drug delivery offers solutions for efficacy, safety and patient compliance of drug therapies. Among these smart devices has emerged a number of wearable technologies, such as microneedle-skin patches and auto-injectors. But despite these advances, how are device developers maximising the benefits of these technologies while meeting patient demands for comfort and convenience? Monica Karpinski investigates. Creating order in uncertain skies In a fast-paced industry like global pharma, where the integrity of sensitive cargoes is key, certification processes serve as a bedrock for consistency and reliability. Andrea Valentino talks to Phil Pluck of the Cold Chain Association and Mateusz Zawadzki of IATA to understand the world of temperature-controlled air cargo shipments, and how certification drives are pivotal in ensuring clear, enforceable standards right across the sector. The cold chain’s climate challenge The pharmaceutical industry is playing its part in a global effort to reduce carbon emissions, so the cold chain is a prime target for technological innovations that can support sustainability, yet many challenges lie ahead. Jim Banks explores the challenges of facilitating pharmaceutical redistribution, minimising waste, meeting net-zero emission targets and maintaining healthcare system capabilities, speaking to Matthew Winterman, senior vice president, global supply chain and strategy at AstraZeneca and Jeffrey Whitford, head of sustainability and social business innovation at Merck’s MilliporeSigma. Encapsulating innovation When it comes to solid oral dosage forms, soft capsules are an essential option for pharmaceutical manufacturers. Developing these soft capsules, however, can often be rather complex. With help from Dr Shawn Wettig of the University of Waterloo, Andrea Valentino investigates, exploring how shells, fillings – and the rising power of sustainability – all come together to create an industry in flux. A spoonful of sugar The unpleasant taste of drugs has long been a reason for poor patient compliance, with pharmaceutical manufacturers developing various techniques for taste masking. Abi Millar talks to Laura Owens, global strategic marketing manager at International Flavors & Fragrances (IFF), about how taste-masking can encourage a more patient-centric approach to drug development. Agility through alliances The past few years have inevitably had an adverse effect on the pharmaceutical and life sciences supply chain, which have only highlighted its importance in the healthcare sector. One element that is typically overlooked, is the importance of relationship management as an operational backbone. Sarah Harris hears from experts in the industry as they explore strategies to cultivate relationships with modern suppliers and ensuring reliable partnerships for sourcing and procurement. A new prescription for packaging Sustainable packaging is rapidly becoming a priority for industries worldwide, spurred by increasing environmental awareness and stringent regulations. However, the pharmaceutical industry faces unique challenges in joining this trend. The EU Packaging and Packaging Waste Directive, aimed at curbing packaging waste and promoting circular economies, has significant implications for pharmaceutical packaging. World Pharmaceutical Frontiers finds out the latest update to the EU’s Packaging and Packaging Waste Directive to shed some light on the current guidelines and recommendations for pharmaceutical packaging and waste. For the opportunity to see your company in World Pharmaceutical Frontiers, please contact Nathan Park.

Vol. 1 2024

Vol. 2 2023

Vol. 1 2023

Vol. 2 2022

Vol. 1 2022

Vol. 2 2021

Vol. 1 2021

Communicate directly with the Pharma community

We continue to invest heavily in the circulation of World Pharmaceutical Frontiers and have created a powerful international readership. Our database of key decision-makers in the pharmaceutical industry accounts for approximately 72% of all purchasing authority.

World Pharmaceutical Frontiers has an ABC audited circulation and a projected readership of over 49,000 (publisher’s survey).

World Pharmaceutical Frontiers reaches a target audience of industry peers with the highest levels of purchasing and decision-making power, including the top decision-makers in the buying chain at the top 50 pharmaceutical and biotechnology companies worldwide, as well as leading CROs and CMOs.

Geo Splits

Target Job function

Level of purchasing involvement

Representative job titles

VP Manufacturing
CEO
Business Unit Manager
Quality Control Director
Managing Director
Technical Director
Head of Operations
President
Chief Scientific Officer

Head of Production
VP of Licensing
Formulation Director
Director of R&D
Innovation Director
Head of Food Engineering
Head of Supply Chain
VP of Purchasing
Procurement Manager

Our readers include professionals from:

Newsletter:

Each week the World Pharma newsletter is sent out to 20,000 digital readers. Covering the latest pharmaceutical manufacturing news from product development, clinical trials, manufacturing, supply chain, outsourcing and regulatory compliance. The newsletter recipients also receive the latest digital version of the magazine also.

We manage the ‘World pharma frontiers forum group on LinkedIn which is a specialist network of about 200 (and counting) pharmaceutical professionals. With regular posts and updates, as well as the latest industry data, it is a great way to engage the sector.

WPF